A crowd of South African men ran through the streets of Johannesburg in purple swim briefs to raise awareness about prostate ...
Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with ...
Posters presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid examined how genomic testing ...
New findings from the UCL-led STAMPEDE Trial may help to identify which men with high-risk prostate cancer could benefit from ...
Prostate cancer is the most common cancer in men – in 2013, it affected more than one million men across the world.
Daily Mail on MSN
Hope for thousands as prostate cancer test identifies who will benefit from aggressive treatment
Thousands of men with high-risk prostate cancer could soon live longer, thanks to a test that helps doctors identify which ...
A new test can identify men who are more at risk of dying from prostate cancer and allow for more personalised treatment.
FITBOOK magazine on MSN
What your blood could reveal about future prostate cancer risk
Can the risk of prostate cancer be detected in the blood years before a diagnosis? Researchers have investigated whether ...
The metastatic outcome depends on the state of disseminated cancer cells (DCCs) leading to overt metastasis or undergoing ...
Capivasertib Plus Abiraterone Shows Promising Survival Results in PTEN-Deficient Prostate Cancer / abiraterone, AKT inhibitor ...
Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation radiopharmaceuticals for the treatment of cancer, today announced compelling results from Part 2 of the ...
Ella Groves, ICNN Senedd Reporter A Senedd Member who is living with prostate cancer has backed calls for the prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results